Citigroup Forecasts Strong Price Appreciation for Kenvue (NYSE:KVUE) Stock

Kenvue (NYSE:KVUE) had its price objective increased by Citigroup from $21.00 to $22.00 in a report published on Monday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other research firms have also commented on KVUE. Barclays decreased their price target on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday. Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 target price on the stock. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus target price of $24.42.

Kenvue Stock Down 0.7 %

Shares of NYSE KVUE opened at $22.76 on Monday. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a fifty day moving average of $22.80 and a two-hundred day moving average of $22.40. The stock has a market cap of $43.50 billion, a PE ratio of 42.94, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.60%. Kenvue’s dividend payout ratio is presently 154.72%.

Institutional Trading of Kenvue

Several institutional investors and hedge funds have recently made changes to their positions in KVUE. Grove Bank & Trust grew its stake in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after buying an additional 571 shares during the period. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.